After the Sichuan 5.12 earthquake, many people in the disaster area suffered from mental health problems. To decrease morbidity from mental disease, the Sichuan authorities worked with diverse hospitals to establish a “three-level network of psychiatric prevention and treatment.” The goal was to disseminate knowledge about prevention and treatment for psychiatric conditions from doctors to recipients, especially regarding symptoms. How to disseminate such knowledge effectively and efficiently deserves study. Based on a sample of 146 doctor-recipient pairs from 52 hospitals in diverse areas of China (including Sichuan, Beijing, and Guangzhou), this study examines the impact of knowledge characteristics, the network status of the doctor, the network status of the hospital with which the doctor is affiliated, and the relationship quality between doctor and recipient on the effectiveness and efficiency of knowledge transfer from the doctor to patient. Findings indicate that high-status doctors are more effective in knowledge transfer. In addition, low-status hospitals were found to have a positive effect on knowledge transfer efficiency. In particular, results highlight the strong positive impact that the quality of the relationship between the doctor and patient has on both the efficiency and effectiveness of knowledge transfer. Finally, findings suggest that the relationship between knowledge characteristics and knowledge transfer is partially mediated by the relationship quality between the doctor and the recipient.

Dr. Katzenstein completed his undergraduate and medical degrees as well as a residency in Internal Medicine and Fellowship training in Infectious Diseases at the University of California San Diego. He continued fellowship training in virology and Infectious Diseases with Dr. Colin Jordan at U.C. Davis, moving to the University of Minnesota to a faculty position in Infectious Disease in 1984. He was a visiting lecturer for two years in the Departments of Medical Microbiology and Medicine at the University University of Zimbabwe as the AIDS epidemic was first recognized in Southern Africa. In 1987, he returned to the U.S. to take up a senior research fellowship at the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration in the Vaccine Branch, evaluating early candidate HIV Vaccines and diagnostics. Dr. Katzenstein returned to California in 1989 to work with Dr. Thomas Merigan and the AIDS Clinical Trials Group. He continues an active collaboration with his colleagues in Zimbabwe and Southern Africa in prevention, perinatal transmission and vaccine research. At Stanford, Dr. Katzenstein participates in studies of multiple drugs and drug combinations in Clinical Trials in the U.S. and Europe and is the principal investigator for Stanford's Virology Service Laboratory in the center for AIDS Research. At Stanford he teaches an undergraduate course in Global AIDS, attends on the Infectious Disease service and supervises both laboratory and clinical fellows conducting AIDS Research. He remains actively involved in studies of HIV infection in Zimbabwe, spending 2-3 months a year in Southern Africa.

Professor Katzenstein's research interests include treatment and evaluation of HIV infection in the United States and Europe through the AIDS Clinical Trials Group (ACTG). His international HIV pathogenesis work includes studies in Zimbabwe, South Africa. The lab currently is focused on drug resistance, envelope tropism and the pathogenesis of HIV.